Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model

JAMA Internal Medicine

Volumn 177, Issue 12, 2017, Pages 1755-1764

  Tasillo, Abriana ^a   Salomon, Joshua A ^b   Trikalinos, Thomas A ^c   Horsburgh, C Robert ^d   Marks, Suzanne M ^e   Linas, Benjamin P ^a,d  

^a BOSTON MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BROWN UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAPENTINE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AMERICAN; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; END STAGE RENAL DISEASE; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MARKOV CHAIN; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT DURATION; TUBERCULIN TEST; UNITED STATES; ANALOGS AND DERIVATIVES; BAYES THEOREM; COST BENEFIT ANALYSIS; DECISION TREE; ECONOMICS; META ANALYSIS; MIGRANT;

ANTITUBERCULAR AGENTS; BAYES THEOREM; COMORBIDITY; COST-BENEFIT ANALYSIS; DECISION TREES; EMIGRANTS AND IMMIGRANTS; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RIFAMPIN; TUBERCULIN TEST; UNITED STATES;

EID: 85038129588     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2017.3941     Document Type: Article

References (47)

1. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2014. https://www.cdc.gov/tb/statistics/reports/2014 /pdfs/tb-surveillance-2014-report-updated.pdf. Published October 2015. Accessed January 15, 2017.
2. Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med. 2011;184(5):590-601.
3. Oza-Frank R, Narayan KMV. Overweight and diabetes prevalence among US immigrants. Am J Public Health. 2010;100(4):661-668.
4. Sterling TR, Villarino ME, Borisov AS, et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23): 2155-2166.
5. Bliven-Sizemore EE, Sterling TR, Shang N, et al; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015;19(9):1039-1044, i-v.
6. Shepardson D, Marks SM, Chesson H, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17(12):1531-1537.
7. Belknap R, Borisov AS, Holland DP, et al. Adherence to once-weekly self-administered isoniazid and rifapentine for latent tb infection: iAdhere [abstract 827LB]. Conference on Retroviruses and Opportunistic Infections. http: //www.croiconference.org/sessions/adherence -once-weekly-self-administered-inh -and-rifapentine-latent-tb-iadhere. Accessed August 28, 2017.
8. Beckles GL, Chou C-F; Centers for Disease Control and Prevention (CDC). Diabetes - United States, 2006 and 2010.MMWRSuppl. 2013;62(3):99-104.
9. Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3-20.
10. Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, Yazdanpanah Y. Cost-effectiveness of QuantiFERON-TB test vs tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis. 2010;14(4):471-481.
11. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA. 2001;286(14):1740-1747.
12. Mazurek GH, Zajdowicz MJ, Hankinson AL, et al. Detection of Mycobacterium tuberculosis infection in United States Navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays. Clin Infect Dis. 2007;45(7):826-836.
13. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):e1-e33.
14. Podany AT, Bao Y, Swindells S, et al; AIDS Clinical Trials Group A5279 Study Team. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322-1327.
15. Sterling TR, Scott NA, Miro JM, et al; Tuberculosis Trials Consortium; AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259); investigators of the TB Trials Consortium; AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607-1615.
16. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2014. https://www.cdc .gov/tb/publications/guidelines/tb-hiv-drugs /recommendations04.htm. Updated September 22, 2014. Accessed January 15, 2017.
17. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167(11):1145-1151.
18. Schackman BR, Fleishman JA, Su AE, et al. The lifetime medical cost savings from preventing HIV in the United States. Med Care. 2015;53(4):293-301.
19. United States Renal Data System. 2015 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD; 2015.
20. Forbes SP, Di M, Salomon JA, Linas BP, Trikalinos TA. Evidence synthesis for diagnostic tests with partially ordered performance and no reference standard. Poster presented at: 38th Annual North American Meeting of the Society for Medical Decision Making; Vancouver, British Columbia, Canada;October 23-26, 2016.
21. United States Census Bureau. Table DP05 - ACS Demographic and Housing Estimates. https://factfinder.census.gov/faces/nav/jsf/pages /index.xhtml. Accessed May 26, 2016.
22. Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol. 2014;79(2):216-225.
23. National Vital Statistics System. 2013 Mortality Tables. Vol. 6, No. 3. https://www.cdc.gov/nchs /data/nvsr/nvsr66/nvsr66-03.pdf. Updated April 11, 2017. Accessed December 14, 2016.
24. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990-997.
25. Desale M, Bringardner P, Fitzgerald S, Page K, Shah M. Intensified case-finding for latent tuberculosis infection among the Baltimore City Hispanic population. J Immigr Minor Health. 2013;15 (4):680-685.
26. Colson PW, Hirsch-Moverman Y, Bethel J, et al; Tuberculosis Epidemiologic Studies Consortium. Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada. Int J Tuberc Lung Dis. 2013;17 (4):473-479.
27. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978;117(6):991-1001.
28. Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection - revisiting and revising concepts. Tuberculosis (Edinb). 2015; 95(4):373-384.
29. Pérez A, Brown HS III, Restrepo BI. Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. Am J Trop Med Hyg. 2006;74(4):604-611.
30. Moran A, Harbour DV, Teeter LD, Musser JM, Graviss EA. Is alcohol use associated with cavitary disease in tuberculosis? Alcohol Clin Exp Res. 2007; 31(1):33-38.
31. Moonan PK, Ghosh S, Oeltmann JE, Kammerer JS, Cowan LS, Navin TR. Using genotyping and geospatial scanning to estimate recent Mycobacterium tuberculosis transmission, United States. Emerg Infect Dis. 2012;18(3):458-465.
32. United States Department of Health and Human Services Center for Medicare Services. Physician fee schedule. http://www.cms.gov /Medicare/Medicare-Fee-for-Service-Payment /PhysicianFeeSched/index.html?redirect =/PhysicianFeeSched. Accessed December 22, 2015.
33. United States Department of Health and Human Services Center for Medicare Services. Clinical laboratory fee schedule. http://www.cms .gov/ClinicalLabFeesched/. Accessed December 22, 2015.
34. Truven Health Analytics. Micromedex 2.0. Drug Topics Red Book Online. http://www .micromedexsolutions.com. Accessed January 13, 2017.
35. Agency for Healthcare Research and Quality. Medical expenditure panel survey. http://meps.ahrq.gov/mepsweb/. Accessed July 15, 2013.
36. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033-1046.
37. Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care. 2004;27(12):2829-2835.
38. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making. 2008;28(4):582-592.
39. Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, Fitzgerald JM. Health state utilities in latent and active tuberculosis. Value Health. 2008;11(7):1154-1161.
40. Miramontes R, Hill AN, Yelk Woodruff RS, et al. Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012. PLoS One. 2015;10(11):e0140881.
41. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107(1):71-76.
42. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc. 1970;26:28-106.
43. Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule: details for title: 16CLAB. https://www.cms.gov/Medicare/Medicare -Fee-for-Service-Payment/ClinicalLabFeeSched /Clinical-Laboratory-Fee-Schedule-Files-Items/16CLAB.html?DLPage=1&DLEntries=10&DLSort =2&DLSortDir=descending. Published December 2015. Accessed May 2016.
44. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project National Inpatient Sample.Washington, DC: US Health and Human Services; 2015.
45. Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
46. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797.
47. Miller TL, Mc Nabb SJN, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoS One.2009; 4(4):1-7.